AUPH vs LGND vs ANIP

For growth investors, ANI Pharmaceuticals, Inc.

(ANIP) is the stronger pick with 43. 8% revenue growth year-over-year, versus 20. 4% for Aurinia Pharmaceuticals Inc. (AUPH). Aurinia Pharmaceuticals Inc. (AUPH) offers the better valuation at 7. 3x trailing P/E (18. 6x forward), making it the more compelling value choice. Analysts rate Aurinia Pharmaceuticals Inc. (AUPH) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Aurinia Pharmaceuticals Inc.

(AUPH) is the cheapest at 7. 3x versus ANI Pharmaceuticals, Inc. at 25. 3x. On forward P/E, ANI Pharmaceuticals, Inc. is actually cheaper at 9. 2x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, ANI Pharmaceuticals, Inc.

(ANIP) delivered a total return of +117. 4%, compared to +49. 2% for Aurinia Pharmaceuticals Inc. (AUPH). Over 10 years, the gap is even starker: AUPH returned +508. 0% versus LGND's +73. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), ANI Pharmaceuticals, Inc.

(ANIP) is the lower-risk stock at 0. 63β versus Ligand Pharmaceuticals Incorporated's 0. 99β — meaning LGND is approximately 58% more volatile than ANIP relative to the S&P 500. On balance sheet safety, Ligand Pharmaceuticals Incorporated (LGND) carries a lower debt/equity ratio of 1% versus 60% for ANI Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ANI Pharmaceuticals, Inc.

(ANIP) is pulling ahead at 43. 8% versus 20. 4% for Aurinia Pharmaceuticals Inc. (AUPH). On earnings-per-share growth, the picture is similar: Aurinia Pharmaceuticals Inc. grew EPS 51. 7% year-over-year, compared to -107. 5% for Ligand Pharmaceuticals Incorporated. Over a 3-year CAGR, ANIP leads at 40. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Aurinia Pharmaceuticals Inc.

(AUPH) is the more profitable company, earning 101. 5% net margin versus -2. 4% for Ligand Pharmaceuticals Incorporated — meaning it keeps 101. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AUPH leads at 37. 1% versus -13. 5% for LGND. At the gross margin level — before operating expenses — LGND leads at 93. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, ANI Pharmaceuticals, Inc.

(ANIP) trades at 9. 2x forward P/E versus 23. 6x for Ligand Pharmaceuticals Incorporated — 14. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ANIP: 47. 8% to $124. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Aurinia Pharmaceuticals Inc.

(AUPH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 86), +508. 0% 10Y return). Both have compounded well over 10 years (AUPH: +508. 0%, LGND: +73. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.